The liquor tau protein and beta amyloid in Alzheimer's disease;Tau protein a beta amyloid v likvoru u Alzheimerovy choroby

Ceska a Slovenska Neurologie a Neurochirurgie

Volumn 70, Issue 1, 2007, Pages 30-36

  Hort, Jakub ^a   Glosova L ^a   Vyhnalek M ^a   Bojar, M ^a   Skoda D ^a   Hladikova M ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Alzheimer's disease; Beta amyloid; Biomarkers; Cerbrospinal fluid; Controls; Frontotemporal dementia; Norms; Phosphorylated tau protein; Total tau protein

Indexed keywords

AMYLOID BETA PROTEIN; BIOCHEMICAL MARKER; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CZECH REPUBLIC; FRONTOTEMPORAL DEMENTIA; HUMAN; NEUROPSYCHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POPULATION RESEARCH; PROTEIN PHOSPHORYLATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 52349097291     PISSN: 12107859     EISSN: 18024041     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 204; 1: 213-25.
2. Vanmechelen E, Vanderstichele H, Hulstaert F, Andreasen N, Minthon L, Winblad B et al. Cerebrospinal fluid tau and beta-amyloid (1-42) in dementia disorders. Mech Ageing Dev 2001; 122: 2005-11.
3. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH et al. Decreased beta-amyloid 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003; 289: 2094-103.
4. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44.
5. Hoglund K, Thelen KM, Syversen S, Sjogren M, von Bergmann K, Wallin A et al. The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2005; 19: 256-65.
6. Andreasen N, Sjogren M, Blennow K. CSF markers for Alzheimer's disease: total tau, phospho-tau a Abeta42. World J Biol Psychiatry 2003; 4: 147-55.
7. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP et al. Improved discrimination of AD patients using beta-amyloid (1-42) and tau levels in CSF. Neurology 1999; 52: 1555-62.
8. Maeck L, Meller J, Otto M, Stiens G, Wiltfang J, Stoppe G. Abeta peptide 1-42, Tau protein and S-100B protein level in cerebrospinal fluid of three patients with primary progressive aphasia. Neurosci Lett 2002; 333: 33-6.
9. Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B et al. Cerebrospinal fluid tau and amyloid beta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett 1999; 273: 5-8.
10. Sjogren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C et at Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001; 70: 624-30.
11. Maddalena A, Papassotiropoulos A, Muller-Tillmanns B, Jung HH, Hegi T, Nitsch RM et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. Arch Neurol 2003; 60: 1202-6.
12. Hu YY, He SS, Wang X, Duan QH, Grundke-Iqbal I, Iqbal K et al. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol. 2002; 160: 1269-78.
13. Pidrman V, Látalová K, Mareš J, Urbánek K, Herzig R, Bekárek V et al. Stanovení tau proteinu a beta-amyloidu jako možných diagnostických markerů demencí. Cesk Slov Neurol N 2004; 5: 330-4.
14. Mareš J, Herzig R, Pidrman V, Urbánek K, Bekárek V, Schneiderka P et al. Tau protein a beta-amyloid jako diagnostické markery Alzheimerovy demence. Čes a Slov Psychiat 2004; 1: 31-5.
15. Petrovitch H, White LR, Ross GW, Steinhorn SC, Li CY, Masaki KH et al. Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a population-based study. Neurology 2001; 57: 226-34.
16. Mathuranath PS, Nestor PJ, Berrios GE, Rakowicz W, Hodges JR. A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology 2000; 55: 1613-20.
17. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-4.
18. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546-54.
19. Bowler JV, Eliasziw M, Steenhuis R, Munoz DG, Fry R, Merskey H et al. Comparative evolution of Alzheimer disease, vascular dementia, and mixed dementia. Arch Neurol 1997; 54: 697-703.
20. Hampel H, Burger K, Preussner JC, Zinkowski R, DeBernardis J, Kerkman D et al. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol 2005; 62: 770-3.
21. Hesse C, Rosengren L, Vanmechelen E, Vanderstichele H, Jensen C, Davidsson P et al. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimers Dis 2000; 2: 199-206.
22. Perry EK, Morris CM, Court JA, Cheng A, Fairbairn AF, McKeith IG et al. Alteration in nicotine binding sites in Parkinson s disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience 1995; 64: 385-95.
23. Martinez-Yelamos A, Saiz A, Bas J, Hernandez JJ, Graus F, Arbizu T. Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis. Neurosci Lett 2004; 363: 14-7.
24. Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 2001; 47: 1776-81.
25. Riemenschneider M, Wagenpfeil S, Diehl J, Lautenschlager N, Themi T, Heldmann B et al. Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration. Neurology 2002; 58: 1622-8.
26. Hampel H, Teipel SJ. Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementia. Dement Geriatr Cogn Disord 2004; 17: 350-4.
27. Sjogren M, Davidsson P, Wallin A, Granerus AK, Grundstrom E, Askmark H et al. Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Dement Geriatr Cogn Disord 2002; 13: 112-8.
28. Sussmuth SD, Tumani H, Ecker D, Ludolph AC. Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. Neurosci Lett 2003; 353: 57-60.